Atopic Dermatitis

New phase 3 data will evidence an FDA application for the biologic as an add-on therapy for patients aged 6-11 years with AD.

A new cohort shows FLG loss-of-function variations are often different among AD pediatric patients with different ancestries.

After showing the ability to regain patients' senses of smell and taste in a pair of phase 3 trials, the biologic becomes the first indicated for CRSwNP.

Preston Klassen, MD, executive vice president of Arena Pharmaceuticals, discusses potential uses for etrasimod outside of inflammatory bowel disease

Patients on 2 different doses of the once-daily oral JAK1 inhibitor reached statistically significant measures for improved symptoms.

Both parents and children with atopic dermatitis often lack answers when it comes to the possibility that food allergies might be causing their skin irritations.

A new NIH-funded study showed that patients with atopic dermatitis may increase their risk of food allergies when they scratch their skin.

This is the third indication for the biologic therapy, following its approvals for adult AD and moderate to severe asthma maintenance care.

The biologic has been previously approved for adult atopic dermatitis and uncontrolled asthma, and is being assesed for another half-dozen allergic/immunologic indications.

Investigators sought to evaluate the efficacy, safety, psychosocial impact, quality of life, adherence to and satisfaction with the treatment of dupilumab and add-on treatment.

An internist’s perspective on which sessions to attend, from melanoma to inflammatory diseases to cosmetic procedures.

In a phase 3 study, dupilumab reduced nasal polyp scores and nasal congestion compared to placebo in patients with chronic rhinosinusitis with nasal polyps.

Compared to a short time of breastfeeding or none, children exclusively breastfed for ≥3 months were less likely to have continued eczema at 6 years old.

How far in advances of care have we come, what issues are most pressing in the field now, and what specialties with be involved in future meetings?

The Program Chair explains how the meeting has improved over 3 decades, and highlights his favorite sessions to come at the 2019 meeting.

The JAK1 inhibitor will be considered as a marketed once-daily therapy for moderate to severe RA in the second half of this year.

Two studies of baricitinib monotherapy for adults with moderate to severe atopic dermatitis met primary efficacy endpoints.

The Regeneron Pharmaceuticals and Sanofi-collaborated biologic became a tour de force in pulmonological care in 2019.

A 48-year-old man presents with severe atopic dermatitis that he’s had since childhood. Can allergy shots succeed where standard treatments failed?

The interleukin pathway-targeting monoclonal antibody has been previously approved for adult atopic dermatitis, and is being considered for a handful more inflammatory or allergic conditions.

Why delving into the symptoms of the most at-need patients is critical for care.

What makes the monoclonal antibody so enticing to the asthma community?

A 200 mg dose of the monoclonal antibody was also shown to significantly reduce ashtma exacerbations over 1 year versus placebo.

In results reported at the European Academy of Dermatology and Venereology Congress, two-week and four-week doses of the subcutaneous drug proved efficacious in improving patient skin.

The patient population tends to have a more unbalanced immune profile to that of European American patients, indicating a potential for tailored treatment options to combat inflammation.

Jonathan Spergel, MD, PhD, and his team linked eosinophilic esophagitis to the condition-based theory. What others are part of the atopic march?

Regeneron has announced that Dupixent, a therapy for adult atopic dermatitis (AD) that is inadequately controlled by existing medications, has been granted marketing and manufacturing authorization in Japan.

Clear or mostly clear skin was achieved by 50/31/14% of patients receiving 30/15/7.5 mg doses of upadacitinib, compared to 2% of patients receiving placebo.

Revisit some of the most popular interviews with physicians and clinicians this past year.

Andrew Alexis, MD, MPH, discussed the current state of care for atopic dermatitis and spoke about how 2017 offered much to look forward to for the field of dermatology.